Acid Ceramidase Deficiency: Farber Lipogranulomatosis and Spinal Muscular Atrophy Associated with Progressive Myoclonic Epilepsy

[1]  K. Sandhoff,et al.  The role of sphingolipid metabolism in cutaneous permeability barrier formation. , 2014, Biochimica et Biophysica Acta.

[2]  P. Elias,et al.  The important role of lipids in the epidermis and their role in the formation and maintenance of the cutaneous barrier. , 2014, Biochimica et biophysica acta.

[3]  T. Levade,et al.  Molecular basis of acid ceramidase deficiency in a neonatal form of Farber disease: identification of the first large deletion in ASAH1 gene. , 2013, Molecular genetics and metabolism.

[4]  R. Hakem,et al.  Systemic ceramide accumulation leads to severe and varied pathological consequences , 2013, EMBO molecular medicine.

[5]  E. Bertini,et al.  Spinal muscular atrophy associated with progressive myoclonic epilepsy is caused by mutations in ASAH1. , 2012, American journal of human genetics.

[6]  F. Jasmi.  A novel mutation in an atypical presentation of the rare infantile Farber disease , 2012, Brain and Development.

[7]  K. Willecke,et al.  Loss of ceramide synthase 3 causes lethal skin barrier disruption. , 2012, Human molecular genetics.

[8]  C. Bedia,et al.  A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease , 2010, Journal of Lipid Research.

[9]  R. Sandhoff.  Very long chain sphingolipids: Tissue expression, function and synthesis , 2010, FEBS letters.

[10]  E. Schuchman,et al.  Acid ceramidase improves the quality of oocytes and embryos and the outcome of in vitro fertilization , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[11]  I. Krägeloh-Mann,et al.  Prosaposin Deficiency and Saposin B Deficiency (Activator-Deficient Metachromatic Leukodystrophy): Report on Two Patients Detected by Analysis of Urinary Sphingolipids and Carrying Novel PSAP Gene Mutations , 2009, American journal of medical genetics. Part A.

[12]  A. Zander,et al.  Farber disease: clinical presentation, pathogenesis and a new approach to treatment , 2007, Pediatric rheumatology online journal.

[13]  Jae-Ho Park,et al.  Acid ceramidase is a novel factor required for early embryo survival , 2007, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  M. Elleder,et al.  Neurolysosomal pathology in human prosaposin deficiency suggests essential neurotrophic function of prosaposin , 2006, Acta Neuropathologica.

[15]  M. Elleder,et al.  Prosaposin deficiency -- a rarely diagnosed, rapidly progressing, neonatal neurovisceral lipid storage disease. Report of a further patient. , 2005, Neuropediatrics.

[16]  E. Schuchman,et al.  The Reverse Activity of Human Acid Ceramidase* , 2003, Journal of Biological Chemistry.

[17]  K. Manova,et al.  Insertional mutagenesis of the mouse acid ceramidase gene leads to early embryonic lethality in homozygotes and progressive lipid storage disease in heterozygotes. , 2002, Genomics.

[18]  F. Lang,et al.  Human Acid Ceramidase , 2001, The Journal of Biological Chemistry.

[19]  T. Linke,et al.  Interfacial Regulation of Acid Ceramidase Activity , 2001, The Journal of Biological Chemistry.

[20]  G. Offerhaus,et al.  Intrauterine Fetal Death Due to Farber Disease: Case Report , 2000, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[21]  K. Uhas,et al.  Bone marrow transplantation for infantile ceramidase deficiency (Farber disease) , 2000, Bone Marrow Transplantation.

[22]  D. Adler,et al.  The human acid ceramidase gene (ASAH): structure, chromosomal location, mutation analysis, and expression. , 1999, Genomics.

[23]  K. Suzuki,et al.  Ceramide accumulation is associated with increased apoptotic cell death in cultured fibroblasts of sphingolipid activator protein-deficient mouse but not in fibroblasts of patients with Farber disease , 1999, Journal of Inherited Metabolic Disease.

[24]  J. Medin,et al.  Retrovirus-mediated correction of the metabolic defect in cultured Farber disease cells. , 1999, Human gene therapy.

[25]  P. Elias,et al.  Sphingolipid Activator Proteins Are Required for Epidermal Permeability Barrier Formation* , 1999, The Journal of Biological Chemistry.

[26]  Y. Hannun,et al.  The role of ceramide in cell signaling. , 1998, Biochimica et biophysica acta.

[27]  P. Courtoy,et al.  Natural ceramide is unable to escape the lysosome, in contrast to a fluorescent analogue , 1998, FEBS letters.

[28]  T. Linke,et al.  Turnover of endogenous ceramide in cultured normal and Farber fibroblasts. , 1997, Journal of lipid research.

[29]  E. Kattner,et al.  Hydrops fetalis: manifestation in lysosomal storage diseases including Farber disease , 1997, European Journal of Pediatrics.

[30]  R. Desnick,et al.  Molecular Cloning and Characterization of a Full-length Complementary DNA Encoding Human Acid Ceramidase , 1996, The Journal of Biological Chemistry.

[31]  H. Moser,et al.  Neurodegenerative course in ceramidase deficiency (Farber disease) correlates with the residual lysosomal ceramide turnover in cultured living patient cells , 1995, Journal of the Neurological Sciences.

[32]  Richard G. W. Anderson,et al.  Compartmentalized Production of Ceramide at the Cell Surface (*) , 1995, The Journal of Biological Chemistry.

[33]  T. Levade,et al.  A family with combined Farber and Sandhoff, isolated Sandhoff and isolated fetal Farber disease: postnatal exclusion and prenatal diagnosis of Farber disease using lipid loading tests on intact cultured cells , 1995, European Journal of Pediatrics.

[34]  R. Desnick,et al.  Purification, characterization, and biosynthesis of human acid ceramidase , 1995, The Journal of Biological Chemistry.

[35]  H. Moser,et al.  Sulfatide and sphingomyelin loading of living cells as tools for the study of ceramide turnover by lysosomal ceramidase--implications for the diagnosis of Farber disease. , 1995, Biochemical and molecular medicine.

[36]  W. Roggendorf,et al.  Prosaposin deficiency: further characterization of the sphingolipid activator protein-deficient sibs , 1993, Human Genetics.

[37]  A. Poulos,et al.  Simultaneous deficiency of sphingolipid activator proteins 1 and 2 is caused by a mutation in the initiation codon of their common gene. , 1992, The Journal of biological chemistry.

[38]  T. Momoi,et al.  Leukocyte and plasma N‐laurylsphingosine deacylase (ceramidase) in Farber disease , 1989, Clinical genetics.

[39]  H. Moser,et al.  A case of combined Farber and Sandhoff disease , 1989, European Journal of Pediatrics.

[40]  K. Wisniewski,et al.  Farber lipogranulomatosis: an unusual presentation in a black child. , 1986, Pediatric neurology.

[41]  H. Moser,et al.  Phenotypic variability in siblings with Farber disease. , 1984, The Journal of pediatrics.

[42]  D. Wenger,et al.  Diagnosis of metachromatic leukodystrophy, Krabbe disease, and Farber disease after uptake of fatty acid-labeled cerebroside sulfate into cultured skin fibroblasts. , 1982, The Journal of clinical investigation.

[43]  H. Moser,et al.  PRENATAL DIAGNOSIS OF FARBER'S DISEASE , 1979, The Lancet.

[44]  C. Schmoeckel,et al.  A specific ultrastructural marker for disseminated lipogranulomatosis (Farber) , 1979, Archives of Dermatological Research.

[45]  H. Moser,et al.  Diagnosis of lipogranulomatosis (Farber disease) by use of cultured fibroblasts. , 1976, The Journal of pediatrics.

[46]  B. Rosner,et al.  CHRONIC RENAL DISEASE , 1975, The Lancet.

[47]  H. Moser,et al.  High performance liquid chromatography of ceramides: application to analysis in human tissues and demonstration of ceramide excess in Farber's disease. , 1974, Journal of lipid research.

[48]  H. Moser,et al.  Ceramidase Deficiency in Farber's Disease (Lipogranulomatosis) , 1972, Science.

[49]  H. Moser,et al.  Farber's lipogranulomatosis. Report of a case and demonstration of an excess of free ceramide and ganglioside. , 1969, The American journal of medicine.

[50]  H. Moser,et al.  Ceramide and Ganglioside Accumulation in Farber's Lipogranulomatosis.∗ , 1967 .

[51]  D. Cogan,et al.  Retinopathy in a case of Farber's lipogranulomatosis. , 1966, Archives of ophthalmology.

[52]  S. Farber,et al.  Lipogranulomatosis; a new lipo-glycoprotein storage disease. , 1957, Journal of the Mount Sinai Hospital, New York.

[53]  R. Zetterström,et al.  Ceramides in a patient with lipogranulomatosis (Farber's disease) with chronic course. , 1971, Scandinavian journal of clinical and laboratory investigation.